Remove Clinical Trials Remove Therapies Remove Trials
article thumbnail

Clinical trial investigates oral MRGPRX2 antagonist in urticaria

Drug Discovery World

The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU). “As we continue to execute on our clinical development plans for EVO756, we are commencing this Phase II trial in 15 study sites across the United States.

article thumbnail

AI digital twins could replace control arm in clinical trials

Drug Discovery World

A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. Diana Spencer, Senior Digital Content Editor, DDW The post AI digital twins could replace control arm in clinical trials appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gene therapy restores vision in first-of-its-kind trial

Drug Discovery World

A gene therapy developed by University of Florida scientists restored useful vision to most patients with rare condition Leber congenital amaurosis type I (LCA1) in a small trial. The trial also tested the safety profile of the treatment. The gene therapy itself caused mild inflammation that was treated with steroids.

Therapies 147
article thumbnail

Acute myeloid leukaemia patient dies in cell therapy clinical trial  

Drug Discovery World

A Phase I clinical trial testing a CAR-T cell therapy treatment in children with acute myeloid leukaemia (AML) has been paused due to a patient’s death. The PLAT-08 clinical trial is a Phase I study of 2seventy bio’s cell therapy SC-DARIC33 in patients with AML.

article thumbnail

FDA clears genetically engineered TIL therapy for solid tumour trials

Drug Discovery World

The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for advanced solid tumour patients. GT201 is designed to boost T cell survival and function by expressing a vital membrane-bound cytokine complex.

article thumbnail

“Game-changing” personalised cancer vaccine enters UK clinical trials   

Drug Discovery World

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. This is a really finely honed tool”. “This is very much an individualised therapy and it’s far cleverer in some senses than a vaccine,” said Shaw. “It in the combination arm and 62.2%

article thumbnail

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

Drug Discovery World

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma.

Therapies 130